Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VD's Model Portfolio & Discussion Thread -- Ignore unavailable to you. Want to Upgrade?

To: Cytokine1 who wrote (6566)	3/26/1999 10:46:00 AM
From: Rocketman	Read Replies (2) \| Respond to of 9719

FDA Approves Sepracor's Xopenex(TM) Worlds' First Single-Isomer Bronchodilator Friday March 26, 6:01 am Eastern Time Company Press Release SOURCE: Sepracor Inc. MARLBOROUGH, Mass., March 26 /PRNewswire/ -- Sepracor Inc. (Nasdaq: SEPR - news) today announced that it has received final approval from the U.S. Food and Drug Administration (FDA) to market Xopenex(TM) (levalbuterol HCl) inhalation solution in two dosage strengths for use with a nebulizer for the treatment and prevention of bronchospasm. Xopenex is the therapeutically active (R)-isomer of racemic albuterol. Racemic albuterol, an equal mixture of (R) and (S) isomers, is the world's leading bronchodilator for asthma, with estimated worldwide sales of $1.2 billion in 1998. In Sepracor's clinical trials, Xopenex demonstrated excellent safety and efficacy, and a duration of action that lasted up to 8 hours. ''It appears the removal of the unnecessary (S)-isomer results in a purer and more potent drug,'' said Harold S. Nelson, M.D., Senior Staff Physician in the Department of Medicine at National Jewish Medical and Research Center and lead investigator in Xopenex Phase III clinical trials. ''For reasons that have not yet been clarified, the (S)-isomer when exposed to the patient in racemic form has been shown to interfere with the overall efficacy of the (R)-isomer.'' MORE AT: biz.yahoo.com

To: Cytokine1 who wrote (6566)	3/26/1999 6:25:00 PM
From: Cytokine1	Read Replies (1) \| Respond to of 9719

VD's MODEL PORTFOLIO 3/26/99 Change -$256 DOWN -0.10% Started 4/9/97, $100K . INDEX ^IXB DOWN -0.62% YTD EQUITY CHANGE -12.5% # CURRENT DAILY CURRENT COST TOTAL %GAIN/ % OF SYMBOL SHRS PRICE CHANGE %CHG VALUE SHR COST LOSS TOTAL ======= ======= ======= ======= ======= ======= ======= ======= ======= ======= MLNM 1000 32.50 -0.31 -0.95% 32500 18.93 18931 71.7% 12.1% SEPR 300 111.56 -6.69 -5.66% 33469 86.00 25800 29.7% 12.5% CLTR 2000 22.25 0.19 0.85% 44500 16.45 32906 35.2% 16.6% CGPI 2000 9.25 0.00 0.00% 18500 9.00 18000 2.8% 6.9% BTRN 6000 2.13 -0.19 -8.11% 12750 2.25 13500 -5.6% 4.8% MOGN 3000 9.00 0.50 5.88% 27000 8.667 26000 3.8% 10.1% INIS 1000 9.50 0.00 0.00% 9500 11.25 11250 -15.6% 3.5% GSII 2000 4.00 0.00 0.00% 8000 4.00 8000 0.0% 3.0% INCY 2000 21.81 0.00 0.00% 43625 28.95 57909 -24.7% 16.3% ABSC 2000 7.13 0.19 2.70% 14250 8.735 17470 -18.4% 5.3% CELG 1000 14.13 0.94 7.11% 14125 15.21 15213 -7.1% 5.3% GZTC 2000 4.94 0.00 0.00% 9875 7.737 15475 -36.2% 3.7% STOCK ______ ______ ______ ______ 268094 260454 2.9% 100.0% SHORT SALE CREDIT ______ ______ 0 MARGIN MTCE. EQUITY 57.0% MIN 30% (106457) BUYING POWER $ ______ 34430 EQUITY (NAV) ______ ______ ______ 161637 100000 61.6% ^IXB INDEX 499.58 -3.14 -0.62% 302.42 65.2% NOTES: OPEN orders subject to available buying power--- INCY limit buy 1000 @ $20.00 3/1/99 -10000 CLTR bought 500 @ $20.00 3/1/99 8500 LGNDW sold 2000 @ $6.00